Capricor Therapeutics, Inc.

📍 San Diego, United States🗓 Founded 2005👥 68 employees💰 Last funded 2017
Biotechnology Research🌐 capricor.com
Website LinkedIn
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for the treatment and prevention of serious diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and complications associated with COVID-19. Capricor is also investigating the field of exosomes and are exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. Our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. Capricor’s lead candidate, CAP-1002, is an allogeneic cardiac cell therapy. CAP-1002 consists of cardiosphere-derived cells, or CDCs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials. Capricor has also established itself as one of the leading companies investigating the field of exosome science. Exosomes are nanosized particles with biologically-active contents that are secreted by cells and serve to direct or re-direct the activities of other cells and are emerging as an exciting class of potential therapeutic agents. We are now focused on developing a precision-engineered exosome platform technology that can carry defined sets of effector molecules including nucleic acids which exert their effects through defined mechanisms of action. We have begun work on our expansion of our exosome platform technology that potentially may be used for vaccine development, vesicle-mediated protein therapies and treatment of inherited diseases.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2005
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Capricor Therapeutics, Inc.?
Capricor Therapeutics, Inc. has 1 investors on record on gritt.io.
When did Capricor Therapeutics, Inc. last raise funding?
The most recent investment in Capricor Therapeutics, Inc. recorded on gritt.io was in 2017.
When was Capricor Therapeutics, Inc. founded?
Capricor Therapeutics, Inc. was founded in 2005.
What industry is Capricor Therapeutics, Inc. in?
Capricor Therapeutics, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Capricor Therapeutics, Inc. based?
Capricor Therapeutics, Inc. is headquartered in San Diego, United States.